DESTINY-Breast05: PROs at #ESMO26
HRQoL was largely maintained with both T-DXd and T-DM1 in high-risk HER2+ early breast cancer with residual invasive disease.
@OncoAlert #BCSM #BreastCancer
637 浏览 · 25 赞 · 7 转发 · 1 回复
Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.org- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert 🔹 T-DXd: Delayed deterioration in pain and arm symptoms. 🔹 T-DM1: Favored social functioning. 🔹 Overall HRQoL and physical/emotional functioning remained comparable. ◽In the curative setting, long-term tolerability and patient experience matter alongside efficacy.
来源：Aya Mohamed | MSc, MD 🎗 · x.com